Investor Centre

Pharmaceutical company Pharmaxis (ASX:PXS) today announced that it has enrolled the first subject into its European paediatric clinical trial evaluating Bronchitol® in cystic fibrosis.

The Phase 2 trial being conducted in Europe and Canada is a requirement of Bronchitol’s earlier European marketing approval for adults and if positive will form part of an application to extend this approval to treat children and adolescents in the EU with cystic fibrosis.

The trial is a 27 week randomised, double-blind crossover investigation of Bronchitol administered twice daily in approximately 160 patients with cystic fibrosis.  The trial is enrolling cystic fibrosis patients aged 6 to 17 years and will assess improvements in lung function, treatment induced sputum weight and safety.

Pharmaceutical company Pharmaxis (ASX:PXS) has  presented  new analyses from the pooled data of its two large scale phase 3 studies in cystic fibrosis illustrating the longer term benefits for patients who respond to Bronchitol® and the product’s value to healthcare systems. The presentation has been made at this year’s European Cystic Fibrosis Society conference in Lisbon, Portugal where it was awarded “Best Poster”.

In line with its recently stated aim to seek commercialisation deals for Cystic Fibrosis products in European markets, Pharmaxis Pharmaceuticals Limited have today announced that they have signed a partnership agreement for UK distribution rights with Yasoo Health Limited, with Pharmaxis taking on the UK sales and marketing of Yasoo’s AquADEKs® range of multi-vitamin products.